Bulk Pharmaceutical API Sources for DOXAZOSIN MESYLATE

Bulk Pharmaceutical API Sources for DOXAZOSIN MESYLATE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		D9815_SIGMA
Molport		MolPort-003-983-427
Hangzhou APIChem Technology		AC-6848

Bulk Active Pharmaceutical Ingredient (API) Sources for: DOXAZOSIN MESYLATE

Last updated: July 29, 2025

---

Introduction

Doxazosin mesylate, a selective alpha-1 adrenergic receptor blocker, is primarily prescribed for hypertension and benign prostatic hyperplasia (BPH). As a critical pharmaceutical component, the quality, sourcing, and supply chain of bulk active pharmaceutical ingredients (APIs) are vital for pharmaceutical manufacturers, regulators, and healthcare providers. Ensuring a reliable and compliant API supply chain for doxazosin mesylate helps maintain drug efficacy, safety, and regulatory adherence.

This article provides an in-depth analysis of global API sourcing options for doxazosin mesylate, considering manufacturers’ profiles, geographic distribution, regulatory compliance, and market trends. It offers insights into established suppliers, emerging players, and strategies to mitigate supply chain risks in the context of global pharmaceutical manufacturing.

---

Overview of Doxazosin Mesylate API

Doxazosin mesylate is chemically characterized as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(1,2-dihydro-2,2-dimethyl-1-oxo-4-quinolinyl) methyl]piperazine methanesulfonate. Its synthesis involves complex chemical processes, requiring high purity standards for pharmaceutical-grade APIs to meet stringent regulatory specifications such as those outlined by the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and other pharmacopoeial standards.

Manufacturers must adhere to Good Manufacturing Practices (GMP) and undergo rigorous quality assurance protocols to supply APIs compliant with international regulatory agencies like the FDA and EMA.

---

Key API Suppliers for Doxazosin Mesylate

1. Major Global API Manufacturers

a. Granules India Ltd. (India)

• A prominent API producer specializing in cardiovascular APIs, including doxazosin mesylate.
• Packaging and supply conform to GMP standards.
• Recognized for competitively priced APIs with reliable supply chains.

b. Hetero Labs Limited (India)

• Offers comprehensive APIs, including boutique cardiovascular agents like doxazosin mesylate.
• Possesses WHO-GMP and USFDA approval for several facilities.
• Focuses on high-quality synthesis processes adhering to international standards.

c. Zhejiang Hisun Pharmaceutical Co., Ltd. (China)

• Leads in APIs for hypertension and cardiovascular indications.
• Fully compliant with GMP and ISO standards.
• Provides scalable manufacturing and bulk APIs tailored for global markets.

d. Mylan N.V. (USA/Global)

• Maintains extensive API manufacturing facilities.
• Certified by USFDA and EMA.
• Supplies pharmaceutical companies with high-purity doxazosin mesylate APIs.

e. Synthesis Pharmaceutical Companies (Italy, Germany, Switzerland)

• Niche European suppliers producing high-grade APIs.
• Focus on quality, stability, and regulatory compliance.
• Serve pharmaceutical cos with stringent quality specifications.

---

2. Emerging and Regional Suppliers

a. Aurobindo Pharma Ltd. (India)

• Expanded API portfolio with cardiovascular agents, including doxazosin mesylate.
• GMP-compliant manufacturing facilities.
• Cost-effective options advantage global markets.

b. Sandoz (Novartis) - Novartis generic division

• Provides high-quality APIs to generic pharmaceutical firms worldwide.
• Emphasizes innovation and compliance with international standards.

c. Zhejiang Kanglong Pharmaceutical Co., Ltd. (China)

• Focuses on small molecule APIs for cardiovascular uses.
• Growing export base with competitive pricing strategies.

---

Regulatory and Quality Considerations

API sourcing hinges heavily on compliance with regulatory standards. Sourcing from FDA- and EMA-approved manufacturers ensures adherence to Good Manufacturing Practices (GMP). Furthermore, suppliers with active cGMP certification and comprehensive quality documentation mitigate supply risks and facilitate faster regulatory approvals for finished formulations.

Quality parameters such as assay purity (>99%), residual solvents, heavy metals, and microbiological limits are non-negotiable. Most suppliers provide Certificate of Analysis (CoA), and regulatory authorities often scrutinize these during batch release and market approval procedures.

---

Regional Dynamics and Supply Chain Risks

India and China dominate global API production for doxazosin mesylate, accounting for over 70% of the market supply. However, geopolitical, logistical, and regulatory challenges introduce risks. Supply disruptions due to trade tensions, pandemic impacts, or regulatory crackdowns can considerably affect drug availability.

Emerging manufacturing hubs in Southeast Asia and Eastern Europe offer diversification, reducing reliance on traditional suppliers. Companies are increasingly adopting dual-sourcing strategies, working with multiple suppliers to mitigate risks and ensure uninterrupted supply chains.

---

Market Trends and Future Outlook

1. API Vertical Integration:
Pharmaceutical companies are increasingly investing in in-house API production to secure supply chains and reduce costs.

2. Environmental and Sustainability Standards:
Rising emphasis on green chemistry practices influences API manufacturing. Suppliers adopting eco-friendly processes gain competitive advantage.

3. Regulatory Stringency:
Enhanced quality standards and global harmonization efforts drive suppliers to upgrade facilities for compliance with International Conference on Harmonisation (ICH) guidelines.

4. Digital Supply Chain Integration:
Use of blockchain and digital tracking improves transparency and traceability of API origins, ensuring quality and authenticity.

---

Conclusions

The global API landscape for doxazosin mesylate is characterized by a diverse array of suppliers, predominantly based in India and China, with several European and North American producers also serving the market. As demand grows concomitantly with hypertension and BPH treatments, maintaining a resilient, compliant, and transparent supply chain remains critical. Regular supplier validation, diversified sourcing, and vigilant regulatory monitoring are essential for pharmaceutical companies to secure quality APIs.

---

Key Takeaways

• Leading global suppliers: Granules India, Hetero Labs, Zhejiang Hisun, Mylan, and Sandoz dominate the doxazosin mesylate API market.
• Regulatory compliance: Prioritize suppliers with FDA, EMA, or WHO GMP certification and transparent quality documentation.
• Supply chain resilience: Diversify sourcing to mitigate geopolitical, logistical, and regulatory risks.
• Emerging markets: Increased API manufacturing in Southeast Asia and Eastern Europe offers strategic opportunities.
• Sustainable manufacturing: Eco-friendly practices and industry certification enhance supplier credibility.

---

FAQs

Q1: What are the primary considerations when selecting an API supplier for doxazosin mesylate?
A1: Key considerations include GMP compliance, regulatory approvals, supply capacity, quality consistency, price competitiveness, and manufacturing capacity.

Q2: How do geopolitical factors impact API sourcing for doxazosin mesylate?
A2: Political tensions, trade restrictions, and tariffs can restrict access to APIs from certain regions, emphasizing the need for diversified sourcing strategies.

Q3: Are there reputable European suppliers for doxazosin mesylate API?
A3: Yes, several European companies, such as those based in Germany, Italy, and Switzerland, supply high-quality APIs, often catering to quality-sensitive markets.

Q4: How can companies ensure compliance of imported API batches for regulatory approval?
A4: Suppliers should provide comprehensive Certificates of Analysis, stability data, and adherence to cGMP standards. Companies also perform their own quality audits.

Q5: What trends are shaping API supply chains for cardiovascular APIs like doxazosin mesylate?
A5: Trends include increased use of green chemistry, digital tracking, regional diversification, and in-house API manufacturing investments.

---

References

1. U.S. Pharmacopeia (USP). Doxazosin Mesylate Monograph. 2022.
2. European Pharmacopoeia (EP). Doxazosin Monograph. 2022.
3. MarketsandMarkets. API Market Analysis, 2023.
4. Pharmaceutical Technology. “Global API Manufacturing Trends,” 2022.
5. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Industry Data, 2022.